Board papers

3 July 2020

00a Document list pdf


Board -2020 -Mtg -3-Doc 00 a




G avi Alliance Board Meeting
24-25 June 2020
Virtual Meeting

Wednesday 24 June : 14.00 -18. 15 Geneva Time
Thursday 25 June : 14.00 -18.00 Geneva Time
Quor um: 14

Document list

No. Document
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes from 4-5 Dec ember 201 9
01c Minutes from 19 March 2020
01d Minutes from 1 1 May 2020
01 e No Objection Consent D ecisions
01f Consent Agenda
01g Consent Agenda: Rev ision of S tatutes and Introduction of Operating Procedures
(To f ollow )
01h Co nsent Agenda : Audit & Investigations R eport
01 i Workplan (To follow)
02 CEO?s Report including Global Vaccine Summit and next steps (To follow)
03 Strategy and impl ications of COVID -19: Gavi 4.0 Progress, Challenges and Risks and
Update on Gavi 5.0 Oper ationalisati on
04 Committee Chair and IFFIm Bo ard reports (To follow)
05 COVID -19: Vaccine Development, Access and Delivery (To follow)
06 Gavi 5.0: Measurement Framework/Strategy Indicators
07 Review of the Gavi Gender Policy
08 Review of decisions ? No paper
09 Closing remarks ? No paper

No. Ad ditional Documents f or Information (on BoardEffect )
A Board and Committee minutes (For information only)
B CEPI Progress Report 201 9

3 July 2020

00b Final Agenda pdf


Board -2020 -Mtg -3-Doc 00b








G avi Alliance Board Meeting
24-25 June 2020
Virtual Meeting



Wednesday 24 June : 14.00 -18.15 Geneva Time
Thursday 25 June : 14.00 -18.00 Geneva Time
Quorum: 14



Agenda








Next Board Meeting s: 16-17 December 2020, Geneva
17 -18 Marc h 202 1, T BD (Board Retreat)
23 -24 June 202 1, Geneva
1-2 December 202 1, Geneva

---
Philip Armstrong , Director, Governance and Secretary t o the Board, +41 22 9 09 65 04, parmstrong @gavi.org
Joanne Goetz , Head, Governance, + 41 22 909 6544, jgoetz@gavi.org
Please note that the Board meeting will be recorded. This recording will be used as an aid to minute t he meeting .
A transcr iptio n of the full proceedings will not normally be made. Shou ld a transcription be made it wil l be used
only as an aid to minute the meeting .




Boar d-2020 -Mtg-3-Doc 00b 2

Board Meeting - DAY ONE - Wed nesda y, 24 June 2020

Item Sub ject Action Schedule

1 Chair?s report
? Declarations of interest
? Minutes
? No Objection Cons ent Decisions
? Co nsent Agenda 1
? Action Sheet
? Wor kplan
Ngozi Okonjo -Iweala, Board Chair
DECISION 14.00 -14. 15
2 CEO? s Report including Globa l Vaccine Summit and next
steps
Seth Berkley, Chief Executive Officer
14. 15-16.00
Break 16.00 -16.10
3 Strategy and implications of COVID -19 : Gavi 4.0 Progress,
Challenges a nd Risks and Update on Gavi 5. 0
Ope rationalisation
Anuradha Gupta, Deputy C EO
Tha bani Maphosa , Managing Director , Country Program mes

Includes co vering the fol lowing:
? Gavi ?s approach to engagement with fo rmer and never -
eligible Middle -Income Countrie s
? Fund ing P olicy Review
? Im pact of COVI D-19 on Gavi countries
? Gavi support t o countries to respond to COVI D-19
DECISION 16.10 -17. 35
Break 17 .35 -17. 45
4 Comm ittee Chair and IFFIm Board reports
? Governance Committee : Sarah Goulding
? Audit and Finance Committee : David Sidwell
? Inve stmen t Committee : Steph en Zinser
? Pro gramme an d Po licy Committee : Helen Re es
? Evalua tion Advisory Comm ittee : Nina Sch walbe
? IFFIm Com pany: Cyrus Ardalan
17. 45 -18. 15
1 Any Board member can ask that any item be removed from the consent agenda for f urth er discussion. S hould
there be any such request, the r elevant discussion will take place on Day Two of the Board meetin g, immedia tely
preceding th e R eview of Decisi ons.

3 July 2020

01b Minutes from 4-5 December 2019


Board -2019 -Mtg -03 1
Minutes




Gavi Alliance Board Meeting
4-5 December 2019
Hyatt Regency Hotel, Delhi, India


1. Chair?s Report

1.1 Finding a quorum of members present, the meeting commenced at 08. 39 local
time on 4 December 2019. Dr Ngozi Okonjo -Iweala, Board Chair, chaired the
meeting.

1.2 The Chair welcomed the Secretary of the Ministry of Health and Family Welfare ,
India , Mrs Preeti Sudan, and her delegation , to th e meeting . She expressed her
appreciation to the Go vernment of India for hosting the Gavi Board in Delhi and
for the welcome event hosted the previous evening. She kindly requested that Mrs
Sudan express, on behalf of the Board and the Gavi Secretariat, s incerest
gratitude and appreciation to Honourable Minister Dr Harsh Vardhan .

1.3 The Chair welcomed new Board members and Alternate Board members, as well
as Nina Schwalbe , Chair of the Evaluation Ad visory Committee, Cyrus Ardalan,
Chair of the International Finance Facility for Immunisation (IFFIm) and other
directors of the IFFIm Board. She noted that departing members would be
recognised for their service at the dinner that evening.

1.4 The Board met in closed session during the afternoon of 3 December to discuss a
number of items including the annual HR Report an d the CEO?s 2019 annual
performance review.

1.5 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack). The Chai r noted that in the context of the items for decision on the agenda,
there were some Board members who would have conflicts of interest and that
these would be raised at the appropriate time and recorded in the applicable
section of the minutes.

1.6 The Boar d noted its minutes from 26 -27 June 2019 (Doc 01b) and 29 July 2019
(Doc 01c) which were approved by no objection on 16 October 2019 and
11 September 2019 respectively . The Board also noted decisions approved by
them by no -objection consent since the last meeting (Doc 01 d), namely, approval
of the 2018 annual financial report and appointments to the Board and Board
Committees.

1.7 The Chair referred to the consent agenda (Doc 01d) where seven
recommendations were being presented to the Board for considera tion. No
requests had been received to place any of the consent agenda items on the main

3 July 2020

01c Minutes from 19 March 2020


Board -2020 -Mtg -01 1
Minutes




Gavi Alliance Board Meeting
19 March 2020
Teleconference


1. Chair?s Report

1.1 Finding a quorum of members present, the meeting commenced at 13. 30 Geneva
time on 19 March 2020 . Dr Ngozi Okonjo -Iweala, Board Chair, chaired the
meeting.

1.2 The Chair commenced the meeting by taking a moment to reflect on the life and
work of Dr Peter Salama , WHO, who had recently passed away . She confirmed to
Board members that she had communicated, also on the Board?s behalf, sincere
condolences to his wife and family and WHO . She indicated that a number of
senior Gavi Secretariat staff had represented Gavi a t the memorial service held in
Geneva for Dr Salama. She informed participants that when the Board has the
opportunity to meet ne xt in person, time will be taken to properly remember Dr
Salama and his life?s work dedicated to global health and humanitarian
endeavours and his many extraordinary achievements.

1.3 The Chair welcomed new Board members and Alternate Board members.

1.4 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack). The Chair asked that Board members who had not yet completed their
annual declaration and submitted it to the Governance team do so as soon as
possible.

1.5 The Chair referred to the consent agenda (Doc 01 b) where a recommendation
from the Governance Committee was being presented to the Board for
consideration. The decisions would be presented at the end of the meeting during
the Review of Decisions.

1.6 It was agreed to dispense with a review of the Board workplan for this meeting.

Decision 1

The Gavi Alliance Board:

a) Appoin ted the following Board Members:
? Zsuzsanna Jakab as Board Member representing WHO in the seat formerly held
by Peter Salama, effective immediately and until her successor is appointed.

 

3 July 2020

01d Minutes from 11 May 2020


Board -2020 -Mtg -02 1
Minutes


With Board for approval by no -objection consent by 22 June

Gavi Alliance Board Meeting
11 May 2020
Teleconference


1. Chair?s Report

1.1 Finding a quorum of members present, the meeting commenced at 14.35 Geneva
time on 11 May 2020 . Dr Ngozi Okonjo -Iweala, Board Chair, chaired the meeting.

1.2 The Chair welcomed participants to the meeting and invited Ambassador Tamaki
Tsukada, Alternate Board member elect, Ja pan, to introduce himself and who
expressed his appreciation at being appointed to the Board .

1.3 She noted that Cyrus Ardalan, IFFIm (International Finance Facility for
Immunisation) Board Chair had joined the meeting for the discussion on Item 03.

1.4 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack).

1.5 It was noted th at the minutes of the 19 March 2020 Board meeting had been
circulated to the Board for approval by no -objection and would be approved by the
end of th e day if no comments were received in the meantime.

1.6 It was agreed to dispense with a review of the Board workplan for this meeting.

1.7 The Chair noted that she had convened two meetings of the All Chairs Group
(ACG) on 21 April and 5 May 2020. During the first meeting , the Board Committee
Chairs had provided valuable feedback from their Committees on issues of
concern relating to the current pandemic and Gavi?s role. During the meeting of 5
May, which had been extended to include a number of additional Board members ,
discussions focussed on a range of issues which are also being presented to the
Board for discussion at this meeting.

1.8 The Chair noted that she will continue to co nvene meetings of the ACG , extending
invitations from time to time to different Board members w ith the relevant expertise,
to ensure that Gavi can remain on top of the COVID -19 issue.

------

2. Update on Replenishment

2.1 Seth Berkley, CEO, introduced this item (Doc 02) highlighting that as the world
grapples with COVID -19 it is natural to focus on what is unprecedented and what
is happening with COVID -19 and this will be discussed later in the meeting. In the

3 July 2020

01e No objection consent decisions pdf

1



Board -2020 -Mtg -3-Doc 01e
Report to the Board
24-25 June 2020
Classified as Internal



Since the December 2019 Board meeting, one decision has been circulated to the
Board electronically for approval by no -objection consent in line with Article 2.7.3.4
of the By -Laws.

On 30 April 2020 , Board members were invited to consider approval of the
appointment of an Alternate Board member .

No objections were received prior to the end of 12 May 2020 and the following
decision was therefore entered into the record:

In accordance with article 2.7.3.4 of the By -Laws, on a no -objection basis, the Gavi
Alliance Board:

Appointed Ambassador Tamaki Tsukada as Alternate Board Member
representing Japan on the donor constituency anchored by the United States
under Article 2.5.2 of the Gavi By -laws, effective immediately and until 31
December 2021.
SUBJECT: NO -OBJECTION CONSENT DECISIONS
Agenda item: 01e
Category: For information

3 July 2020

01f Annex A Guiding Principles on Gender Balance for Board and Committee Nominations pdf










DOCUMENT ADMINISTRATION


VERSION
NUMBER APPROVAL PROCESS DATE
1.0 Approv ed by: Gavi Alliance Board 17 June 2010
Effective from: 17 June 2010
Next review: At the request of the Board
2.0 Reviewed and recommended by:
Gavi Governance Committee 30 April 2020
Approved by: Gavi Alliance Board 24 June 2020
Effective from: 1 July 2020
Next review: As and when requested Gavi Alliance
Guiding Principle s on Gender
Balance for Board and
Committee Nominations
Version 2 .0
Doc 01f - Annex A






2
Gavi Alliance
Guiding Principles on Gender Balance for
Board and Committee Nominations
1. Purpose
1.1. The purpose of these Guiding Principles is to establish a framework through
which the Gavi Alliance Board can endeavo u r to ensure gender balance across
Gavi?s governance structures, to the extent possible.
1.2. The Governance Committee has the responsibility to monitor adherence to the
principles on behalf of the Board.
2. Mandate of the Governance Committee
2.1. The Gavi Alliance Board and Board Committee Operating Procedures state, at
Section 2 , p ara graph 2.3 that:
? The Governance Committee may establish, subject to the approval of the Board,
minimum criteria as to the qualifications and competencies of all Board Members,
provided such criteria shall not unreasonably restrict or interfere with the right of
any Eligible Or ganisation or Eligible Constituency to select its Board member(s)
according to its Selection Process . The criteria for Board membership shall be
consistent with the guiding principles on gender for Board and Board Committee
nominations , specifically, that gender balance in all areas of Gavi Alliance work
should be ensured, including throughout the governance structures, to the extent
possible. ?
2.2. Under Section 3, p ara graph 3.2 of the Gavi Alliance Board and Board Committee
Operating Procedures , the Governance Committee may decide not to nominate a
person designated by an applicable Eligible Organisation or Eligible Constituency
as its Representative Board Member if ?the person so designated does not meet
the minimal criteria established pursuant to p aragraph 2. 3 ?.
3. Acceptable gender balance
3.1. The Governance Committee shall ensure that a ratio of 60/40 male/female
among Board Members , Alternate Members , Board Committee Members and
Board Advisory Body Members 1
is esta blished and maintained . For the purposes
of this calculation, the Board Members , Alternate Members , Committee Members
and Advisory Bodies shall be assessed both as separate groups and as an
aggregate . The gender balance shall be deemed to be within the acceptable
range if there is no mor e than 60% of any one gender.
3.2. At the time of reviewing nominations, the Governance Committee will be made
aware of the current gender balance and the impact of putting any nominations
forward to the Board.
3.3. The Governance Committee will strive to give preference to nominating a
designated representative or proposed candidate of the under - represented
gender for appointment as Board Member , Alternate Board Member , Board
Committee Member and/or Board Advisory Body Member until such time as the
gender balan ce of the Board Members or Alternate Board Members has been
brought within the acceptable range.

1
Includes the All Chairs Group, the Evaluation Advisory Committee (EAC) and the Independent
Review Committee (IRC)
Doc 01f - Annex A

3 July 2020

01f Annex B Whistleblowing Policy pdf






DOCUMENT ADMINISTRATION



VERSION
NUMBER APPROVAL PROCESS DATE
1.0
Prepared by: Governance May 2009
Approved by: Gavi Alliance Board 3 June 2009
Effective from: 3 June 2009
2.0
Revised by: Director of internal
Audit (as requested by Gavi
Alliance Board Chair)
March 2011

Reviewed by:
Legal
Director of Human Resources
Interim CEO
Executive Team (subgroup on
corporate issues)
Staff Council
March -July 2011
Approved by: Executive Team 10 August 2011
Effective from: 1 September 2011
3.0
Updated by: Executive Office
(change to Compliance Officer
contact details)
21 January 2013
4.0 Revised by: Legal February 2020

Reviewed by:
MD Audit & Investigations
Director of Governance
Director of Human Resources
CEO
Deputy CEO
Staff Council

Recommended by : Gav i Alliance
Audit and Finance Committee

Approved by: Gavi Alliance Board

February ? June 2020







22 June 2020

Effective from: 1 July 2020
Next Review : Every five years
Gavi Alliance
Whistleblow ing Policy
Version 4.0

3 July 2020

01f Consent Agenda REVISED as at 22 June 2020 pdf

1



Board -2020 -Mtg -3-Doc 01f
Report to the Board
24 -25 June 2020

Section A: Introduction
Eight recommendations are being presented to the Board under the Consent
Agenda for consideration. Detailed information on each of the items can be found
in the relevant Committee paper in a dedicated folder on BoardEffect at :
https://gavi.boardeffect.co.uk/workrooms/6459/resources/33754
Section B: Actions requested of the Board
The Gavi Alliance Board is requested to consider the following recommendations
from the Gavi Alliance Governance Committee and Finance and Audit Committee .
Decision One ? Board and Board Committee member appointments
The Gavi Alliance Governance Committee recommend s to the Gavi Alliance
Board that it:
a) Approve the exceptional extension of Stephen Zinser as:
? Unaffiliated Board member effective 1 July 2020 and until 30 June 2021;
and
? Chair of the Investment Committee effective 1 July 2020 and until 30 June
2021.
b) Approve the exceptional extension of David Sidwell as:
? Unaffiliated Board member effective 1 January 2021 and until 31 December
2021;
? Chair of the Audit and Finance Committee effective 1 January 2021 and
until 31 December 2021;
? Member of the Mar ket -Sensitive Decisions Committee effective 1 January
2021 and until 31 December 2021; and
? Member of the Investment Committee effective 1 January 2021 and until
31 December 2021.
c) Appoint the following Board Member:
? Mahima Datla as Board Member representing the vaccine industry
developing countries in the seat currently held by Sai Prasad effective
1 July 2020 and until 30 June 2023.
SUBJECT: CONSENT AGENDA REVISED AT 22 JUNE 2020
Agenda item: 01 f
Category: For Decision

3 July 2020

01g Annex A Revised and Updated Gavi Alliance Statutes pdf

















Gavi Alliance





STATUTS du 2 9 octobre 2008
(Modifi? pour la derni?re fois le 24 - 25 juin 2020 )



La version fran?aise, originale, fait foi






























Gavi Alliance





STATUTES of 29 October 2008
( Last modified on 24 - 25 June 2 020 )



Traduction a nglaise
















Doc 01g - Annex A

2 / 19
I. DISPOSITIONS G ENERALES

Article 1 Nom

Sous le nom " Gavi Allian c e ", il est con s ti tu? une
fondation ? but non lucratif r?gie par les pr?sents
Statuts et par les articles 80 et s ui v an ts du Code
civil suisse.

La Gavi Alliance est inscrite au Registre du
Commerce de Gen?ve et plac?e sous la
surveillance de l'Autorit? f? d?r ale d e
Survei llanc e d es Fondations (ci - apr?s " l? Autorit?
de Surveillance ").


Article 2 But

La Gavi Alliance a pour but de promouvoir la
sant?, (i) en fournissant des vaccins et les moyens
pour les administrer aux habitants des pays les
plus pauvres, ( ii) en c ontribua nt ? la recherche et
au d?veloppement de vaccins de premi?re
n?cessit? en faveur des pays en d?veloppement et
(iii) en fournissant un appui dans le cadre de la
r?alisation des buts susmentionn?s en aidant ?
renforcer les syst?mes de sant? e t l es so ci?t?s
c ivile s q ui soutiennent de tels buts dans les pays
en d?veloppement.

Dans le cadre de ce large but, la Gavi Alliance
concentrera son travail sur l?aide ? l?am?lioration
de la vaccination et l'immunisation dans les pays
les plus pauvres. A cet ef fe t, la Ga vi Al lia nce
?uvre en tant que partenariat public - priv?
international innovateur qui met en relation
diverses organisations et groupes engag?s
activement dans le soutien ? l?immunisation dans
les pays b?n?ficiaires , tels que gou vernements,
orga ni sations des N ati ons Unies, producteurs de
vaccins, fondations, organisations non
gouvernementales et instituts de recherche ainsi
que des individus b?n?ficiant d?exp?rience dans
plusieurs domaines, dont le secteur priv?, qui,
ensemble app ortent l?gitimit ?, cr?dibilit ? et
expertise technique. La Gavi Alliance, I. G E NERAL PROVISI ONS

Article 1 Na me

An independent non - p rofit foundation within the
meaning of Articles 80 et seq. of the Swiss Civi l
Code is referred to as ?the Gavi Alliance ? .


The Gavi All iance shall be register ed at the
Regi stry of Com merce of the Cant o n of Geneva
a nd placed under t he supervision of the Sw iss
Supervisory Board for Foundations (hereafter
referred to as the " Supervi sory Authority ") .


Article 2 Purp ose

The pu rpose of the G avi Alliance is to prom ote
health by: (i) provid ing va ccines and t he means
to d eliver such vacci nes to people in the poo rest
countries; (ii) facilitating the research and
development of vaccines o f primary interest to
the developi ng world; an d (iii) to pro vide support
in connect ion with achie ving the fo regoin g
purposes b y helping to strengthen health care
systems and civil societies supporting such
purposes in the developing world.


Within this br oad purpose, the Gavi Alliance wil l
focus its work in suppor t of improvement of
vac cination and i mmuni s ation in th e poorest
c o untries. To t his effect, the G avi Alliance works
as an innovative international public - private
partnership, which brings together various
organisations and constitu encies activ ely engaged
in supporting immunisatio n in implement ing
co untries ? s u ch as Governm ents, United Nations
organis ations, vacci ne manufacturers,
foundations, nongovernmental organisations and
research in stitutes, as well as individuals with
private s ector and other experience , which
together provid e legitimacy , cred ibility and
technical exp ertise. Recogni s ing and draw ing on
the ma ndates and responsibilities of all
Doc 01g - Annex A

3 July 2020

01g Annex B Gavi Alliance Board and Committee Operating Procedures pdf


June 2020
BOARD AND BOARD COMMITTEE
OPERATING PROCEDURES


Purpose and definitions
These Operating Procedures apply to the governance, administrative and advisory bodies
as list e d in Article 8 of the Statutes . Unless defined in these Operating Procedures all
capitalised terms used in these Operating Procedures shall have the meaning given to
such terms in the Statutes (as amended from time to time). Section mean s sections of
these Operating Procedures. ?Business day? means a working day in the Canton of Geneva.
Board
1. Appointment Process
1.1. The Board has formed a ? Governance Committee ? responsible, among other
things, for recommending the appointment of qualified candidates to the
Board in accordance with the Statutes a nd these Operating Procedures.
1.2. The Governance Committee duties, whether or not delegated to another Board
C ommittee (as defined in Section 1 8 ) or a sub - committee, shall be subject to
the p rovisions of Section 1 8 .
1.3. The Governance Committee shall recommend the nomination of candidates for
Board membership in accordance with the procedures herein.
1.4. The Governance Committee may establish, subject to Board approval,
additional procedures with respect to the desig nation and nomination of
Board members as are reasonably necessary to carry out these provisions.
1.5. The Governance Committee may establish, subject to the approval of the
Board, minimum criteria as to the qualifications and competencies of all Board
members, provided such criteria shall not unreasonably restrict or interfere
with the right of any Eligible Organisation or Eligible Constituency to select its
Board member(s) according to its Selection Process. The criteria for Board
membership shall be c onsistent with the guiding principles on gender for
Board and Board Committee nominations.




Doc 01g - Annex B

3 July 2020

01g Consent Agenda Revision of Statutes and Intro of Operating Procedures pdf

1



Board -2020 -Mtg -3-Doc 01g
Report to the Board
24 -25 June 20 20

Section A: Executive Summary
? At its meeting of 11 February 2020, Governance Committee members noted
a proposal to:
o review and update Gavi?s Statutes to remove some ambiguities that
currently exist and provide more clarity on a number of its provisions ;
o retire Gavi?s By -laws and replace them with a set of Operating
Procedures for the Board and Board Committees falling under the
purview of the Board; and
o incorporate any elements of the By -laws into the Statu tes which might
be required to ensure compliance with the Swiss Civil Code (as Gavi is
a Swiss Foundation).
? This paper seeks to provide some furthe r context to that proposal and the
ensuing work which has been overseen and endorsed by the Governance
Committee , which now recommends to the Board that it approv e the revised
and updated Statutes and the new Operating Procedures and retire the By -
laws .
? Th e revised and updated Statutes have received the prior approval of the
Swiss Supervisory Authority for Foundations (Supervisory Authority) and
the new Operating Procedures in place of the By -laws have been cleared
by the S upervisory Authority.
Section B: Statutes, By -laws and Operating Procedures
Introduction
1.1 When the Gavi Alliance was set up as a Swiss Foundation in 2009, the
Board approved the Gavi Statutes and the Gavi By -laws as the two principal
governing documents of the organisation.
1.2 Articles 80 to 8 9 of the Swiss Civil Code provide the legal framework under
which Swiss Foundations may operate and determine that their work is
supervised by the Supervisory Authority, which falls within the Federal
Ministry of the Interior.
SUBJECT: CONSENT AGENDA: REVISION OF STATUTES AND
INTRODUCTION OF OPERATING PROCEDURES
Agenda item: 01g
Category: For Decision

3 July 2020

01g Consent Agenda Revision of Statutes and Intro of Operating Procedures To follow pdf

1



Board -2020 -Mtg -3-Doc 01g
Report to the Board
24 -25 June 20 20

















SUBJECT: CONSENT AGENDA: REVISION OF STATUTES AND
INTRODUCTION OF OPERATING PROCEDURES
Agenda item: 01g
To follow

3 July 2020

01h Annex A Consent Agenda Audit and Investigations Report pdf

Report to the Board
Board -2020 -Mtg -3-Doc 01h -Annex A

Annex A: Re cut of A&I 2020 plan



3 July 2020

01h Consent Agenda Audit and Investigations Report pdf

1



Board -2020 -Mtg -3-Doc 01h


Section A: Executive Summary
Context
The Managing Director of the Audit and Investigations (A&I) function is required to
report to the Board at least annually. Given the constrain ts on time for this meeting,
it has been agreed with the Board Chair to postpone th at report until the December
meeting. C onsequently , certain items for immediate update are presented in this
paper.
Questions this paper addresses
? The Board has been briefed previously on the need to undertak e an
External Quality Assessment (EQA) of the A&I function by an independent
third party , a requirement of the professional standards by which the
function operates. This assessment was undertaken in late 2019. What are
the results of the EQA?

? In the light of the COVID -19 pandemic, the planned activities of the A&I
function for 2020 have been significantly recast. What considerations have
been taken in to account in revising the plan, and what coverage of risk is
achieved consequently?

? Certain updates are required in A&I ?s Terms of Reference (ToR) , the charter
which sets the foundations for the conduct of the A&I activity and the scope
of its operation . Why are c hanges to the ToR required , and what are they?
What is the basis of the Board ?s approval ?
Concl usions
The EQA resulted in an overall rating of ?generally complies? (which is the highest
achievable). A&I was assessed against 62 criteria and satisfied them all with out
qualification or recommendation . Certain ?value -added? observations , not critical,
were made by the assessors for the further development of the A&I function.
The A&I 2020 plan has been revised with a consideration of : the changing risk
profile which Gavi faces ; the practical effects of not being able to travel to countri es
to conduct programme audits ; and the compromised availability currently of
management and staff members to engage with A&I . The revised plan, approved
by the AFC, is shown at A nnex A.
SUBJECT : CONSENT AGENDA : AUDIT AND INVESTIGATIONS
REPORT
Agenda item: 01 h
Category: For Decision
Report to the Board
24-25 June 20 20

3 July 2020

01i Board Workplan As at 17 June 2020 pdf

Classified as Internal #
Gavi Alliance Board Workplan
Gavi Board Paper Type No Obj Oct Dec Mar/Apr June Nov/Dec Mar/Apr June Nov/Dec Mar/Apr June Nov/Dec Mar/Apr June Nov/Dec Mar/Apr June Nov/Dec
A.Strategy/Performance/RiskCEO's Report CEO's Report Discussion 2016-2020 Strategy 2016-2020 Strategy: Progress, Risks and Challenges Discussion 2021-2025 Strategy Gavi 5.0 Decision Measurement Framework (Targets & Indicators) Gavi 5.0: Operationalisation Decision Decision Decision Funding Policies* Gavi 5.0: Operationalisation Decision Decision Programmatic Approaches TBD TBD Portfolio Management Processes TBD TBD Review of Partner Engagement Model Gavi 5.0: Operationalisation Decision Decision Innovation (including private sector partnerships) TBD TBD Middle Income Countries (MICs) TBD Decision Decision Risk and Asurance Report Risk and Assurance Report Decision Decision Decision Decision Decision Decision Decision B.Vaccines & SustainablityTyphoid TBD Information Information Pneumococcal AMC (Advance Market Commitment) TBD Information Inactivated Polio Vaccine (IPV) co-financing approach TBD TBD TBD COVAX TBD TBD C.PolicyFragility, Emergencies, Refugees Policy TBD TBD Supply & Procurement Strategy Review of Gavi's Supply and Procurement Strategy Decision Decision Transparency and Accountability Policy Decision D.Country ProgrammesNigeria TBD Information Information Information Information Information Information Information PNG TBD Information Information Post-Transition Support (e.g. Angola, Timor-Leste) TBD Information E.Finance/Audit & Investigations Annual Accounts Annual Financial Report Decision Decision Decision Decision Decision Decision Decision Financial Forecast Financial Update, including forecast Decision Decision Decision Decision Decision Decision Decision Budget Financial Update, including forecast Decision Decision Decision Decision Decision Audit & Investigations Report Audit & Investigations Report Information Information Information Information Information Information Information F.GovernanceBoard Chair Appointment Board Chair Appointment Decision Decision Board Vice Chair Appointment Consent Agenda Decision Decision Decision Decision Committee Chair Appointments Consent Agenda Decision Decision Decision Decision Decision Decision Board and Committee Appointments Consent Agenda Decision Decision Decision Decision Decision IRC Appointments Consent Agenda Decision CEO Appointment Consent Agenda Decision Decision Secretary Appointment Consent Agenda Decision Treasurer Appointment Consent Agenda Decision Amendments to Governance Documents (Statutes, By-Laws, Committee Charters) Consent Agenda Decision Decision IRC Terms of Reference TBD Decision Audit & Investigations Terms of Reference TBD Decision G.ReportingCommittee Chair Reports Committee Chair and IFFIm Board reports Information Information Information Information Information Information Information Information Information Information Information Information IFFIm Chair Reports Committee Chair and IFFIm Board reports Information Information Information Information Information Information Information Information Information Information Information Information Replenishment/Resource Mobilisaton TBD Discussion Discussion HR Report Closed Session Information Information Information Information Information Information Annual Report on Implementation of the Gender Policy TBD Information Information Information Information Information Information Information CEPI Progress Report Annex to Board pack/On BE as additional materials Information Information Information Information Information Information Information Information Information Information Information Information Board and Committee minutes Annex to Board pack/On BE as additional materials Information Information Information Information Information Information Information Information Information Information Information Information H. Pre-Board Technical Briefing SessionsTBCTBC
*Includes Eligiblity & Transition Policy, Co-Financing Policy, HSIS Support Framework, CCEOP
Last updated - 17 June 2020
Next Board Meetings : 16-17 December 2020, Geneva 17-18 March 2021, TBD (Board Retreat) 23-24 June 2021, Geneva 1-2 December 2021, Geneva
2020 2021 2022 2023 2024 2025
Gavi 4.0 Gavi 5.0
Board-2020-Mtg-3-Doc 01i

6 July 2020

02 CEO's Report (Français) pdf

1




Board -2020 -Mtg -3-Doc 02
Rapport au Conseil
d?administration
24 -25 juin 2020


Le 17 juin 2020

Chers membres du Conseil d'administration,
Au d?but du mois, le Royaume -Uni qui s?est montr? si accueillant, a organis? le
Sommet mondial sur la vaccination 2020 , troisi?me conf?rence ? virtuelle - des
donateurs de Gavi . Cet ?v?nement a connu un succ?s remarquable, non
seulement parce que nous avons r?ussi ? d?passer l?objectif minimum de
7,4 milliards de dollars US que no us nous ?tions fix?, mais aussi parce qu?il a
permis d?exprimer concr?tement la solidarit? mondiale et de reconna?tre
l'importance de la vaccination et de la t?che accomplie par Gavi. Notre mission
n'a jamais ?t? aussi pertinente qu'aujourd'hui .
La COVID -19 a fait basculer notre monde, et nous auron s ? en affronter les
cons?quences sanitaires, ?conomiques et sociales pendant encore un certain
temps. Le SRAS -CoV -2, virus responsable de la COVID -19, s?est propag ? en
quelques mois dans 180 pays. Comme nous en avons d?j? discut? au sein du
Conseil d?administration , les ?pid?mies de ce genre sont une des cons?quences
in?vitables de l?? vol ution . Cette pand?mie met en lumi?re l'importance de la
vaccination dans la lutte contre les maladies infectieuses et les pand?mies , de la
r?silience des syst?mes de sant? et du r?le de Gavi pour la s?curit? sanitaire au
niveau plan?taire . Mais tout cela n?est possible que si nous parvenons ? atteindre
toute s les population s, ce qui confirme le bien -fond? de l?approche que nous
avons adopt?e pour Gavi 5.0 en d?cidant de centrer nos actions sur les individus
et les communaut?s les plus marginalis?s et de mettre en place des syst?mes
permettant d?atteindre ceux qui ont ?t? laiss?s de c?t? .
La COVID -19 a impos? de nouvelles fa?ons de penser et de travailler, ce qui est
valable ?galement pour les r?unions de gouvernance. Nous avons d? all?ger
notre ordre du jour . Afin de privil?gier les temps de discussion, nous avons
supprim? les traditionnels discours d? introduction et avons ouvert un forum de
discussion sur BoardEffect pour que les membres du conseil d'administration
puissent poster des commentaires et des questions sur les documents avant la
r?union. Richard Hatchett, directeur g?n?ral de la Coalition pour les innovations
en mati?re de pr?paration aux ?pid?mies (CEPI, pour Coalition for Epidemic
Rapport du Directeur ex?cutif

6 July 2020

02 CEO's Report pdf

1



Board -2020 -Mtg -3-Doc 02

Report to the Board
24-25 June 2020


17 June 2020

Dear Board members ,
Earlier this month, the UK ? our gracious hosts ? convened Gavi?s third donor
pledging conference, the virtual Global Vaccine Summit 2020. The event was an
outstanding success, not only because we were able to exceed our target of at
least US$ 7.4 billion, but also because of the global solidarity and recognition of
the importance of immunisation and the work of Ga vi. Never has our mission
been more relevant than it is now.
COVID -19 has turned the world upside down with health, economic and societal
implications we will be grappling with for some time to come. SARS -CoV -2, the
virus responsible for COVID -19, was able to traverse 180 countries in a few short
months. As we have discussed at the Board, such outbreaks are an evolutionary
inevitability. This outbreak underscores the importance of vaccines in fighting
infectious disease and controlling pandemics, of resilie nt health systems and of
Gavi?s central role in achieving global health security. But we can only do that if
we reach everyone, and this reinforces our approach in Gavi 5.0 of focusing on
the most marginalised and building out systems to reach the unreache d.
COVID -19 has forced new ways of thinking and working, and that also holds true
for governance meetings. We have had to streamline our agenda. To maximise
time for discussion, we will not have our usual introductory presentations and
have set up a Discu ssion Board on BoardEffect for Board members to post
comments and questions on the papers ahead of the meeting. We will also have
Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations
(CEPI) addressing the Board. CEPI has become an e ven closer partner to Gavi
through our joint work on COVID -19 vaccines and their use of the International
Finance Facility for Immunisation (IFFIm) to channel support from Norway.
In the face of COVID -19, I would like to start with an acknowledgement of t he
health care workers globally who are on the frontlines of this pandemic, many
working without personal protective equipment (PPE) or other basic supplies.
Alliance partners including both WHO and UNICEF have lost invaluable staff to
Report of the Chief Executive Officer

6 July 2020

03 Strategy and implications of COVID 19 pdf

1



Board -2020 -Mtg -3-Doc 03

Section A: Executive Summary
This report presents an overview of how the Alliance is delivering against its
Strategic Goals including a holistic view across the Alliance?s portfolio of support
to countries including vaccine programmes, Health System and Im munisation
Strengthening (HSIS) support and technical support provided under the Partners?
Engagement Framework (PEF) , and on the associated risks 1.
As the COVID -19 pandemic continues to unfold, this report also provides an
overview on the immediate impact on immunisation programmes and
achie ving the targets of Gavi 4.0 (Section B) , a brief update on the Alliance?s
proactive response to the crisis (Section C) and the potential implications on
Gavi 5.0 operationalisation (Section D) over the next 18 months . A detailed view
on the impact on immunisation programmes , Gavi?s response and the implications
on Gavi 5.0 was discussed at the 11 May 2020 Board meeting and is made
available to the Board through regular Situation Reports on BoardEffect.
At its 26 -27 May 2020 meeting the PPC discussed Gavi?s adaptive response to
the COVID -19 pandemic and was supportive of the three pillars of the
approach , i.e. the immediate support for country response, maintain ing and
restor ing immunisation services over the next 18 months , and responding to the
fiscal impact of the pandemic on immunisation programmes .
As part of that the PPC agreed with the importance of supporting former Gavi -
eligible countries to address the emerging risks of backsliding in
immunisation programme performance due to COVID -19. In response to these
developments, and in light of the pausing of the Gavi 5.0 Middle Income County
(MICs) approach for the duration of the pandemic , the PPC recommen ds that the
Board allocate targeted Gavi funding (excluding vaccine financing) to
mitigate backsliding risks, where well justified and needed, in these
countries. This time -limited and targeted support aims to specifically address the
unique circumstances brought about by COVID -19 and is therefore not expected
to create a precedent that might detract from Gavi?s sustainability approach.

1 Associated risks refer to the top risks described in the 2019 Risk & Assurance Report (see
https://www.gavi.org/news/document -library/gavi -risk -and -assurance -report -2019 ). The COVID -19
pandemic has led to an extraordinarily uncertain environment with a significant impact on Gavi?s
risk profile, as described on a high -level in the AFC update on risk management (Annex C)
SUBJECT :
STRATEGY AND IMPLICATIONS OF COVID -19 : GAVI 4.0
PROGRESS , C HALLENGES AND RISKS AND UPDATE ON
GAVI 5.0 OPERATIONALISATION
Agenda item: 03
Category: For Decision
Report to the Board
24 -25 June 2020

6 July 2020

03 Annex A Updated Alliance KPI dashboard pdf


Re port to the Report to the Board
Board -2020 -Mtg -3-Doc 03-Annex A


Annex A : Updated Alliance KPI dashboard
Classified as Internal
BOARD & COM M ITTEE ATTENDANCE
GENDER BALANCE
Partners3
1
2
3
4
5
6
7
SFA/PEF ACHIEVEM ENTS
CSO ENGAGEM ENT
PLEDGE CONVERSION
DONOR ENGAGEM ENT IN COUNTRY
END 2019TARGET: N/A EVALUATION ALIGNM ENT
END 2019TARGET: N/A COUNTRY REPORTING
END 2015TARGET: 85%
55%
END 2019TARGET: 50%
END 2019TARGET: 100%
END 2019TARGET: N/A
END 2019TARGET: 95%
Governance4
1
Secretariat & partners1
2
4
5
6
VACCINE INTRODUCTIONS
END 2019TARGET: 56 NEW VACCINE COVERAGE
END 2019TARGET: 90%
END 2019TARGET: 90% HSS PROPOSAL QUALITY
END 2019TARGET: 100% HSS FUND UTILISATION
END 2019TARGET: 75% HSS GRANT TARGETS
END 2019TARGET: 50% 34%
Secretariat
OPERATIONAL DEM AND FORECAST
PROGRAM M E FINANCE FORECAST
SPEED OF CASH GRANT DISBURSEM ENTS
END 2019 TARGET: 9 months AUDITS ON TRACK
END 2019TARGET: 80% RISK M ANAGEM ENT PLAN PROGRESS
END 2019TARGET: 60% OPERATING EFFICIENCY
TARGET: N/A?
END 2019 TARGET: +/-10%
END 2019TARGET: +/-10%
1
2
2016 ?2020 INDICATORS ALLIANCE PROGRESS
4
Gavi Programme and Policy CommitteeUPDATED: 29 April 2020
PARTNER GROUP PEF
PEF
CSO
DONORS
DONORS
COUNTRIES
TCA ACTIVITIES ON TRACK
0 EVALUATIONS
Health system strengtheningTargeted country assistanceStrategic focus areaPartners' engagement frameworkCivil society organisation
HSSTCASFAPEFCSO
END 2019TARGET: 90% 88%
END 2019TARGET: 40%
71%
82%
END 2018BASELINE: 25
END 2018BASELINE: 96%
END 2018BASELINE : 10%
END 2018BASELINE: 50%
END 2018BASELINE: 58%
2018BASELINE : 50%
END 2018BASELINE: 17.5 months
END 2018BASELINE :18 %
END 2018BASELINE : 87%
2017BASELINE $283k:
END 2018BASELINE : -10%
END 2018BASELINE : -19%
END 201 8 BASELINE: 32 %
END 2018BASELINE :89 %
END 2018BASELINE : 59%
END 2018BASELINE : 95%
END 2018BASELINE : 94%
END 2018BASELINE : 5
2017BASELINE : 92%
END 2018BASELINE : 87%
END 201 8 BASELINE : 42%
ON TRACKMODERATE DELAYS / CHALLENGESSIGNIFICANT DELAYS / CHALLENGES
11
TRACKING TREND ONLY
50%
95%
323
94% 61%
88%
96%
-6%
14%
278K
NO UPDATE AT THIS REPORTING PERIOD
3M EASLES CAM PAIGN COVERAGE
10.9months
4
5
6
3
2
1
2
45%
59
86%
No update
+17%
99% No update

6 July 2020

03 Annex B Strategy Indicators as originally defined pdf


Re port to the Report to the Board

Board -2020 -Mtg -3-Doc 03-Annex B



Annex B : 2016 -2020 Strategy progress dashboard with original indicator definitions




Classified as Internal
2
3
Improve sustainability3 Market shaping4 Accelerate vaccines1 Strengthen capacity2
2016 ?2020 INDICATORS STRATEGY PROGRESS
5
Gavi Programme and Policy CommitteeUPDATED: 29 April 2020
1
EQUITY: GEOGRAPHIC DISTRIBUTION
ROUTINE IM M UNISATION COVERAGE 1
2
3
4
5
EFFECTIVE VACCINE M ANAGEM ENT
DATA QUALITY
PENTA1 COVERAGE & DROP -OUT
INTEGRATED HEALTH SERVICE DELIVERY
CIVIL SOCIETY ENGAGEM ENT
2
3
4
1
COUNTRY INVESTM ENT IN VACCINES
COUNTRIES ON TRACK TO TRANSITION
INSTITUTIONAL CAPACITY
CO-FINANCING COM M ITMENTS
2
3
4
1
VACCINE PRICE REDUCTION
VACCINE INNOVATION
HEALTHY M ARKET DYNAM ICS
SUPPLY SECURITY
Measles -containing vaccine 1 stdose Percentage pointPentavalent 1 stdose Pentavalent 3 rddose
MCV1
PPPenta1Penta3
CURRENT: + 1PP 2020 TARGETPENTA3 85%MCV1:83% 2015 BASELINEPENTA3: 80% MCV1:78%
CURRENT: + 1PP 2020 TARGET 26% 2015 BASELINE16%
2020 TARGET43%** 2015 BASELINE16%
2020 TARGET 38% 2015 BASELINE28%
2020 TARGETPENTA1: 90% DROP-OUT: 4% 2015 BASELINEPENTA1: 86% DROP-OUT: 7%
2020 TARGET100% 2015 BASELINEN/A 2020 TARGET55%
100%2020 TARGET100% 2020 TARGET11/11
$15.57 2020 TARGET N/A1
2020 TARGET 10
2020 TARGET 6/11
55%2020 TARGET43%**
2020 TARGET **
2015 BASELINE45%
2020 TARGET 75% 2015 BASELINE63%
2015 BASELINEN/A
2015 BASELINEN/A
2015 BASELINE85% 2015 BASELINE7/11
2015 BASELINE$20
2015 BASELINE0
2015 BASELINE1/11
BREADTH OF PROTECTION
PENTA381%
CURRENT: + 1PP 2020 TARGET 63% 2015 BASELINE31%
52%
24% MCV181%
87%
45%
21%
8/11
10
3/11 4EQUITY: WEALTH
CURRENT: + 1PP 2020 TARGET 45% 2015 BASELINE35%5EQUITY: M ATERNAL EDUCATION
CURRENT: + 1PP 2020 TARGET 40% 2015 BASELINE30%
ON TRACKMODERATE DELAYS / CHALLENGESSIGNIFICANT DELAYS / CHALLENGES
2
NO UPDATE AT THIS REPORTING PERIOD
24
35%
32%
60%
7PP
35%
56%
1Not published due to commercial sensitivity** Revised baselines and targets Approved by the Board in November 2018
Indicators reported as originally defined
16%
TRACKING TREND ONLY/ DATA INCONCLUSIVE2
No update
No update
No update
No update

6 July 2020

03 Annex C AFC update on risk management pdf

0014
0003
0003 0003
0003
0024
0003
0035
0024
0019
0003
0003
0036 0003
00780003
0053
004C
00560057
0036
0003
0014 0048
004B
0050
0024
0053 0003
0014 0014
0003
0045
0057
0044
0044
0050
0048 0003
0014 002C
0046
00550048004A 000F
0047
005A0044005900480056
00550048
0044 0036000F0036
0046 00030033 0011
0056004C0057
0050
0057 0003
00140003 004B 0011
0057
00360003 0035002C
0024 00130019
0026 0029
Doc 03 - Annex C
0015
0003
0003 00780003 0003 003500480053
0078 0003 0003
0024
0003 00460052
000B004C0051
004C005100560057
004B
004C00510046004F0058 002C
0047 004C00560003
005A00520055004E004C0051
0044
004C00510046005500480044005600480047
0014
0050
0044
0045
0057
00560057
0014 004A
00560058 0050005A
0044
0044
00460052
0053
0044
0057
0047004A 0003
0045
0051
0050
0024
0014 002C
005A 000F
0044
0044
0048
0049
0052
0044
00460052
005A004C
0048 0003
0014 005A004C
002A
0053
004A
005A004B004C0046004B
004C00510046004800510057 00030052
Doc 03 - Annex C

6 July 2020

03 Annex D Update Funding Policy Review pdf

Report to the Board
Board -2020 -Mtg -3-Doc 03-Annex D

Annex D : Update on Funding Policy Review
As part of operationalising Gavi 5.0, the Secretariat conducted a two -phase review of
Gavi?s existing funding policies: Eligibility & Transition Policy, Co -Financing Policy
and the Health System & Immunisation Strengthening (HSIS) Support
Framework 1. The purpose of this annex is to inform the Board of the status of this
Funding Policy Review (FPR) in light of the COVID -19 pandemic , and to provide
greater detail on the decision points in Doc 03 .
Scope , Context and Approach
1.1 The FPR is an integrated review to update the core policies which define Gavi
funding to countries 2. Until now, the se policies have been developed and
updated individually and separately . This concurrent review enabled an aligned
update to the funding policies, simplifying burdensome processes and
realign ing objectives and incentives .
1.2 The se three policies describe Gavi?s principles and approach to the
funding it provides. Implementation experience indicates that th ese policies
have function ed largely well under the stable ?standard? conditions for
which they were developed, alongside the Fra gility, Emergencies, Refugees
Policy 3 and Gender Policy 4.
1.3 The Eligibility & Transition Policy articulates which countries can access
Gavi support and how this support phase s out over time. It enshrines the key
principles of time -limited and catalytic support focused on the poorest countries
in the world, linked to a country?s ability to pay as proxied by its gross national
income per capita (GNI p.c.). It also provides a clear, institutiona lised pathway
for a country?s eventual exit from Gavi support. In conjunction, t he Co -
financing Policy helps build long -term financial sustainability of vaccines
introduced with Gavi support by requiring countries to invest resources to
procure a certain s hare of these vaccines.
1.4 The Health System and Immunisation Strengthening (HSIS) Support
Framework sets out the objectives, funding levels and essential requirements
for HSIS support (including how health system strengthening (HSS) support is
allocated acr oss countries), to contribute to sustainable improvements in
1 The HSIS support framework operates in a similar manner as a Gavi policy, but with a greater level of
detail. The FPR seeks to resolve this inconsistency with other Board -approved policies. This includes
health system strengthening (HSS) grants, vaccine i ntroduction grants (VIGs) and operational support
for campaigns (Ops). The review also covered the Cold Chain Equipment Optimisation Platform
(CCEOP), which is not currently part of the HSIS framework. 2 While the FPR recommends alignment of funding to cou ntries with funding for technical assistance
through the Partners? Engagement Framework (PEF), PEF itself is included in a separate 5.0
operationalisation workstream on ?Partnerships?. 3 The Fragility, Emergencies and Refugees Policy provides flexibilitie s to a country facing significant
challenges due to exceptional circumstances as identified by humanitarian and emergency response
partners. This policy went into effect in July 2017 and is not in scope for the FPR . 4 A revised Gender Policy (see Doc 04 ) is also being brought to the Board for approval at this meeting .
It is a programmatic policy designed to ensure that a gender lens is taken in Gavi?s approach to
supporting countries and country programming of Gavi?s support to ensure access to immunisatio n for
all.

6 July 2020

03 Annex E Gavi 5 0 Approach to MICs pdf

1


Re port to the Board
Board -2020 -Mtg -3-Doc 03-Annex E

Annex E: Gavi 5. 0 MICs Approach and COVID -19
Introduction
1.1 In June 2019, the Board agreed that the Alliance?s approach to former
Gavi -eligible countries be institutionalised in Gavi 5.0. They requested
that the Secretariat develop an approach with the objectives of introducing
key missing vaccines and preventing backsliding in immunisation
cov erage levels post -transition. At that time, t he envisaged package of
support for former Gavi -eligible countries included political advocacy,
technical assistance, innovation, market shaping, and catalytic financial
support to jumpstart vaccine introduction s.
1.2 Building on this foundation, t he Board also request ed the Secretariat to
explore how some elements of this approach could be ex tended to
some 1 never Gavi -eligible middle -income countries (MICs ). The
engagement with never Gavi -eligible MICs would have a particular focus on
new vaccine introductions , thereby address ing the inter -country equity
challenge that is impossible to disregard in light of Gavi?s ambitious goal of
?leaving no -one behind wit h immunisation?. The Board approved a funding
envelope of up to 3% of Gavi 5.0 planned expenditure (approximately
US $ 300 million) for the delivery of the MICs Approach.
1.3 Following this decision last year , the Secretariat ha s been developing the
detailed MICs Approach in close collaboration with countries, donors,
partners, expanded partners, and other key stakeholders . The Secretariat
had prepared to bring this approach to the PPC and Board for decision in
May and June 2020 . Section 2 of this paper outlines the Approach that had
been developed prior to COVID -19 and Section 3 indicates the implications
of COVID -19 on this Approach and how the Secretariat will act in response .
The MICs Approach that had been developed prior to COVID -19
2.1 The MICs Approach , as had been prepared for presentation to the PPC and
Board, ha d two primary objectives: to prevent backsliding in vaccine
coverage in former Gavi -eligible countries , and to drive the sustainable
introduction of key missing vacci nes in both former and select never
Gavi -eligible countries . Alongside these primary objectives, the Approach
ha d a number of important secondary objectives: to improve inter - and intra -
country equity ; to maintain and improve access to sustainable vaccine
pricing ; to open up access to new technologies and innovations ; and to
mobilise and maximise domestic resourcing .
2.2 The Approach was designed to leverage the existing expertise and
activities of Alliance partners and expanded partners , as well as to build
1 Never Gavi -eligible countries in scope of the MICs Approach included countries with a GNI p.c.
up to $6,000 and that were missing at least one of three key vaccines (PCV, Rotavirus and HPV).
The Secretariat was also proposed the inclusion of some select s mall island states , in line with the
World Bank definition of IDA .

6 July 2020

03 Annex F Risk implication and mitigation pdf

Report to the Board
Board -2020 -Mtg -3-Doc 03-Annex F

Annex F: Risk implication and mitigation
? COVID -19 creates unprecedented risks to the economies, health systems and
immunisation programmes of Gavi -supported countries. A failure to respond
adequately risks undermining the progress that has been made in
strengthening immunisation coverage, equity, financing and programmes in
current and former Gavi -eligible countries. If these countries see a sustained
backsliding in immunisation coverage, or even drop a vaccine, this will pose
serious questions about the sustainability of the Gavi model. The finan cial cost
for countries to address gaps in coverage or to reintroduce vaccines will be
significant. The approach described in this paper should help mitigate those
risks.
? There is a risk that if many countries are granted flexibilities, this could make
the exceptions in the FER policy common across the portfolio and thereby limit
implementation of Gavi?s standard policies. There is also a risk that the Alliance
will have to make decisions on adjusting support to countries rapidly and with
inadequate informa tion, which could result in suboptimal allocation of resources
or fiduciary risk. To mitigate this, the Secretariat will develop a clear approach
to determine when a nd how flexibilities are granted and new HSIS funding
applications will be subject to exter nal review to ensure that the requested
flexibilities are justified and proportionate. The Secretariat will systematically
track all flexibilities and develop a clea r approach to transition countries to
updated ?standard? policies post -COVID.
? There is a ri sk that the additional flexibilities will result in accelerated
expenditure from Gavi?s HSIS and PEF envelopes over the next 1 -2 years.
While this will help countrie s to respond to the pandemic, it would also mean
that additional funding would be required to ensure countries continue to have
access to adequate support in the latter years of Gavi 5.0. To mitigate this risk,
the Secretariat will continue to monitor the financial impact of the flexibilities
granted and report to the AFC, PPC and Board.
? There i s a risk that Gavi?s support is inadequate to mitigate the impact of
COVID -19 on countries? immunisation programmes and this could result in a
resurgence of VPD outbreaks and mortality. To mitigate this risk, the Alliance
will engage closely with other dev elopment partners to ensure a coordinated
approach to help countries maintain and restore immunisation programmes as
part of a PHC response. The Alliance will continue to monitor the performance
of immunisation programmes and report to the Board if further interventions are
needed.
? There is a risk that the Secretariat and Alliance partners may have inadequate
capacity to manage the COVID -19 response, while also maintaining existing
programmes and preparing for implementation of Gavi 5.0. To mitigate this risk,
the Alliance will seek to coordinate support for COVID -19 recovery with
implementation of Gavi 5.0, and will closely monitor if existing resources are
adequate or surge capacity is required.

6 July 2020

04 AFC Chair Report to Board June 2020 pdf

1




Board -2020 -Mtg -3-Audit and Finance Committee Chair Report


Section A: Introduction
? This report provides the Board with an overview of the activities of the Audit
and Finance Committee ( AFC ) since the Gavi Alliance Board last met in
December 2019 .
? The AFC met twice ( 13 February and 6 May) and will be meeting on 22 June
and 23 July 20 20 . Closed session and calls were also held to discuss AFC
procedural matters and brief ing s on specific topics including regular
updates on the risks and operational management of C OVID -19.
? Subjects reviewed in February and May are noted under Section B and
matters to be reviewed in upcoming meetings ( 22 June and 23 July) are
under Section C.
Section B: Subject matters reviewed
1) Financial review
? Noted that the Secretariat has effectively managed its operati ons in a
business continuity mode .
? Regular engagement of the AFC with the respective teams in the
Secretariat involved in the C OVID -19 operational response to ensure that
systems, processes and procedures operate effectively to ensure team
health & safety , business continuity and safeguarding of Gavi?s assets . No
significant issues raised.
? Noted that preparation of 2019 Financial Statements is well underway with
no significant issu es raised.
? Newly effective accounting polic ies required by US accounting rul es ha ve
been implemented .
? New regulatory requirements under the Swiss Code of Obligations (SCO)
comprising of standalone financial statements for Gavi and documentation
of internal control system processes have required significant effor t,
including by the World Bank (WB) .
? Noted t he productive collaboration between the Secretariat and the WB to
accommodat e the requirements .
SUBJECT: AUDIT & FINANCE COMMITTEE CHAIR REPORT
Agenda Item: 4
Category: For Information
Report to the Board
24 -25 Ju ne 20 20

6 July 2020

04 EAC Chair Report to Board June 2020 pdf

1



Board -2020 -Mtg -3-Evaluation Advisory Committee Chair Report


Section A: Introduction
? This report provides the Board with an overview of the activities of the
Evaluation Advisory Committee ( EAC ) since the December 2019 Board .
? Due to COVID -19 travel restrictions, the EAC had a virtual meeting on 25
March 2020 . Many items scheduled for the m eeting were postponed .
? Since the last report to the Board, the EAC has:
o Discussed novel evaluation methods in the face of COVID -19
impacting on traditional data collection approaches. The EAC
discussed the utility of a pulse survey to understand the impact of
COVID -19 on Routine Immunisation and that considerations and
questions around COVID -19 be considered as a part of ongoing
evalu ations ;
o Provided guidance on the draft questions for the final evaluation of
the A dvance Market Committment (AMC) ;
o App roved the addition of the Fragility, Emergencies , Refugees Policy
to the 2020 Evaluation Workplan ;
o Provide d guidance to the Secretari at on how to strengthen utility of
learning products and communication of evaluation findings ; and
o Provided detailed fee dback on the Terms of Reference ( ToR ) for the
evaluations of Gavi?s Engagement with the Private Sector and the
Supply and Procurement Strategy. Final reports are expected Q4
2020.
? The EAC will focus on the 2021 workplan and supporting Gavi to develop a
robust Theory of Change for Gavi 5.0 and an evaluation work plan which
reflects the impact of recent Gavi Alliance B oard decisions related to
COVID -19. This should include how COVID -19 programming affects Gavi ?s
other investments.
SUBJECT : EVALUATION ADVISORY COMMITTEE CHAIR REPORT
Category: For Information
Report to the Board
24 -25 June 2020

6 July 2020

04 GC Chair Report to Board June 2020 pdf

1



Board -2020 -Mtg -3-Governance Committee Chair Report

Section A: Introduction
? This report provides the Board with an overview of the activities of the
Governance Committee (GC) since the Board last met in December 2019 .
? The GC met virtually on 11 February 2020, 17 March 2020 and 30 April
2020 .
? In addition to some routine business su ch as B oard and Committee
nominations and the recruitment of Unaffiliated Board members, Committee
discussions focused on work in relation to the (i) Board Chair recruitment
process, (ii) organising principles for the Donor and Research and Technical
Healt h Institutes constituencies , (iii) Guiding Principles on Gender for Board
and Committee nominations , (iv) a mendments to the Secretariat Conflicts
of Interest Policy and (v) discussions related to revising the Gavi Statutes,
retiring the Gavi By -laws and replacing it with the new Board and Board
Committee Operating Procedures.
? The Board, at its meeting on 17 March 2020, already approved
amendments to the Gavi By -laws and Governance Commi ttee Charter on
the recommendation of the Governance Committee.
? In addition, a nomination for an Alternate Board member submitted to the
Governance Committee at its meeting on 30 April 2020 has already been
circulated to the Board for no objection consent .
? The GC will meet on 18 June 2020 a nd it is expected that further
recommendations will be put forward to the Board on the consent agenda
at its June meeting in relation to Board and Committee appointments,
Independent Review Committee appointments, appointment of a new
Secretary , amendments to the Gavi Statutes and approval of new Board
and Board Committee Operating Procedures .
? The GC Chair report is attached in the form of a presentation as Annex A .
Annexes
Annex A : Governance Committee Chair report
SUBJECT : GOVERNANCE COMMITTEE CHAIR REPORT
Category: For Information
Report to the Board
24-25 June 2020

6 July 2020

04 IC Chair Report to Board June 2020 pdf

1



Board -2020 -Mtg -3-Investment Committee Chair Report


Section A: Introduction

? This report provides the Board with a n overview of an extraordinary and
unprecedented period in financial markets, reviews investment performance
during this period and updates on the activities of the Investment
Committee . The Committee met twice in the first half of 2020.

? At the start of 2020, the economic backdrop was benign. Market consensus
was that the emerging coronavirus threat from Wuhan could be contained
within China. Effectively the virus was viewed as a human tragedy but not
a market moving event.

? Market panic then ensu ed in February and March as investors reali sed that
the C OVID -19 pandemic could not be contained without putting much of the
global economy into an induced coma. The intensity and volatility of the sell -
off left an indelible mark. The US S&P 500 equity in dex went from peak to
trough ( -34%) in 24 trading days. By comparison, during the 2008 Global
Financial Crisis, the S&P 500 took 356 trading days from peak to trough ( -
57%). While much of the media focus was on equity markets, extreme
market volatility spr ead into other asset classes, including commodities and
investment grade and high yield fixed income credit markets. Developed
market sovereign bonds benefitted from a flight to quality, but all risk assets
fell in unison and the benefits of asset class di versification temporarily
disappeared.

? Having reported a positive return of 12.4% in 2019, the long -term portfolio
suffered a drawdown of -10.6% in Q1 2020 at the height of the C OVID -19
panic. Since March month -end, the portfolio has meaningfully recov ered
such that the year -to -date loss at May month -end is a manageable -3.4 %.

? The drawdown in Q1 2020 was in line with the risk measures and scenarios
(Value at Risk) previously presented to the Board, but performance through
month -end March was nevert heless underwhelming. The Investment
Committee believed heading into the pandemic that markets were fully
valued and had added strategies to the portfolio that were only modestly or
in some cases negatively correlated with overall market volatility. These
included Long/Short equity allocations in the Equity sector and a Dispersion
SUBJECT: INVESTMENT COMMITTEE CHAIR REPORT
Agenda item: 4
Category: For Information
Report to the Board
24 -25 June 2020

6 July 2020

04 IFFIM Chair Report to Board June 2020 pdf

1



Board -2020 -Mtg -3-IFFIm Chair Report



Section A: Introduction
? This report provides an overview of IFFIm?s contribution to Gavi and the
results of the 2021 -2025 replenishment.
? IFFIm is an innovative financing mechanism with strong donor support and
recognised as a pioneer in socially responsible investing.
? With the successful replenishment of IFFIm, its financial strength and
efficienc y will continue to support Gavi for the 2021 -2025 strategic period.
? The Gavi Board?s approval of engaging IFFIm to support CEPI as an
approved Gavi programme, has allowed for additional incremental pledges
and leverages IFFIm?s ability to frontload long -te rm donor pledges for
immediate needs.
? IFFIm is expected to provide US$1.475 billion in assured resources for the
2021 -2025 strategic period with added value through its financial flexibility.
? The IFFIm Chair report is attached in the form of a presentation as Annex
A.
Annexes
Annex A : IFFIm Chair report
SUBJECT : IFFIM CHAIR REPORT
Agenda item: 4
Category: For Information
Report to the Gavi Board
24-25 June 2020

6 July 2020

04 PPC Chair Report to Board June 2020 pdf

1



Board -2020 -Mtg -3-Programme and Policy Committee Chair Report


Section A: Introduction
? This report provides the Board with an overview of the activities of the
Programme and Policy Committee ( PPC ) since the Board last met in
December 2019 .
? The PPC met by videoconference on 26 -27 May 2020. During the meeting,
the Committee discussed a number of important topics for the Alliance and
agreed on recommendations which are being put forward to the Board at its
June meeting for consideration.
? The PPC Chair report is attached in the form of a presentation as Annex A
and the PPC recommendations to the Board are attached as Annex B.
Annexes
Annex A : PPC Chair report
Annex B : PPC recommendations to Gavi Alliance Board
SUBJECT : PROGRAMME AND POLICY COMMITTEE CHAIR REPORT
Category: For Information
Report to the Board
24-25 June 2020
www.gavi.orgPROGRAMME AND POLICY
COMMITTEE CHAIR REPORT
BOARD MEETING
Helen Rees
24 - 25 June 2020, Virtual Meeting
Annex A

6 July 2020

05 COVID 19 Vaccine Development Access and Delivery Corrected pdf

1



Board -2020 -Mtg -3-Doc 05


Section A: Executive Summary
Context
In the context of the broader COVID -19 response, the Gavi Board has expressed
its support for Gavi to partner with others to make affordable vaccines available
and accessible to those most in need and planning for deployment of vaccine s so
they can be delivered as soon as they are available.
Questions this paper addresses
? What progress has Gavi made together with partners in securing access to
sufficient and timely supply to suitable COVID -19 vaccines and planning for
future delivery inc luding potential requirements for cold chain equipment ?
Conclusions
The Access to C ovid Tools (ACT) Accelerator has been established as a
collaboration mechanism for COVID -19 diagnostics, therapeutics and vaccines.
Within the ACT Accelerator Vaccines Pillar, Gavi is leading a workstream on
vaccine procurement and delivery at -scale, while the Coalition for Epidemic
Preparedness Innovations (CEPI ) is leading on development and manufacturing
and WHO is leading on policy and allocation. All three partners have committed to
working together closely to support a seamless effort toward the rapid dev elopment
and equitable delivery of COVID -19 vaccines.
With regards to securing supply of COVID -19 vaccines , Gavi , together with
partners, has launched the COVID -19 Vaccines Global Access (COVAX) Facility.
The Facility aims to pool demand and resources tow ard securing access to future
supply of COVID -19 vaccines. All countries are invited to participate in th is global
Facility, which will utilise a mix of manufacturer -specific volume guar antees and
market -wide demand guarantee s. The Secretariat is continuing to work closely
with stakeholders to complete the design and begin operation alisation of the
Facility , including raising the necessary funding .
Coordination across the ACT Vaccines Pillar workstreams will be essential t o
ensure that characterist ics of developed vaccines are appropriate for Gavi -
supported countries . Early discussions have been initiated within the Alliance on
potential vaccine use scenarios and the country -level planning, training and
community and social mobili sation interventions that will be required for successful
SUBJECT : COVID -19 VACCINE DEVELOPMENT, ACCESS AND
DELIVERY
Agenda item: 05
Category: For Decision
Report to the Board
24-25 June 20 20

6 July 2020

06 Gavi 5.0 Measurement Framework Strategy Indicators pdf

1



Board -2020 -Mtg -3-Doc 06


Section A: Executive Summary
Purpose of the report
Following discussion s at the October 2019 and May 2020 Programme and Policy
Committee (PPC) meetings , the Board is requested to provide guidance on the
Gavi 5.0 measurement framework. An Alliance Technical Working Group (TWG)
is advising on development of the framework and e nsuring alignment with
Immunization Agenda 2030 (IA2030). An iterative process with broad consultations
to vet indicators has included consultations with countries, partners, Civil Society
Organisations and other Alliance stakeholders at the Gavi 5.0 Count ries and
Partners Retreat.
Questions this paper addresses
? How is the 5.0 measurement framework being developed?
? Which indicators are currently suggested for 5.0 strategy performance
monitoring, at which levels, and which require further development?
? How do es the COVID -19 pandemic affect finalisation of the 5.0
measurement framework?
The COVID -19 pandemic will delay finalisation of the 5.0 measurement framework,
largely due to the challenge of setting targets given uncertain 2020 baselines .
Section B: Gavi 5.0: Measurement Framework/Strategy Indicators
Facts and Data
1.1 Proposed Gavi 5.0 mission and strategy indicators are intended to measure
progress towards the goals and objectives as described in the Gavi 5.0
strategy framework ?one -pager? ( Annex A), approved by the Board in June
2019 . They focus on key portfolio -level impacts, outcomes or outputs , with
shared accountability across the Alliance . They represent a subset of the
metrics to be used for monitoring progress along Gavi?s result chai n.
1.2 The following principles guide the development of Strategy Performance
Monitoring (details provided in Doc 06 to the October 2019 PPC meeting):
SUBJECT : GAVI 5.0: MEASUREMENT FRAMEWORK/STRATEGY
INDICATORS
Agenda item: 06
Category: For Guidance
Report to the Board
24 -25 June 2020

6 July 2020

06 Annex A Gavi 5 0 one pager June 2020 pdf

Report to the Board
Board -2020 -Mtg -3-Doc 06-Annex A

Annex A: Gavi 2021 ?2025 Strategy Fr amework

6 July 2020

06 Annex B Draft Gavi 5 0 Indicator Dashboard June 2020 pdf

Report to the Board
Board -2020 -Mtg -3-Doc 06-Annex B

Annex B: Draft Gavi 5.0 Indicator Dashboard

6 July 2020

06 Annex C Summary of Gavi 5 0 Indicator Definitions June 2020 pdf

Report to the Board
Board -2020 -Mtg -3-Doc 06-Annex C
Annex C : Summary of Indicator Definitions 1
Table 1: Summary Descriptions and Use Cases for Mission Indicators
ID Indicator What would be measured How it would be used
M.1 Under -5 mortality rate
Average probability of a child
born in any of the Gavi -
supported countries dying
before they reach the age of
five.
Communicate Gavi?s
contribution to child mortality
reduction
M.2 Future deaths averted 2
Number of anticipated future
deaths prevented as a result of
vaccination with Gavi -funded
vaccines in the countries we
support
Demonstrate Gavi impact on
vaccine preventable disease
(VPD) mortality.
M.3 Future DALYs averted
Number of disability -adjusted
life years (DALYs) averted as a
result of vaccination with Gavi -
supported vaccines.
Demonstrate Gavi impact on
VPD mortality and morbidity.
M.4 Zero -dose children
(Equity indicator)
Reduction in number of zero -
dose children
Measure of extending routine
immunisation services to
missed communities. An
equity measure.
M.5
Unique children
immunised with Gavi
support
Number of children immunised
with the last recommended
dose of a Gavi -supported
vaccine delivered through
routine systems
Demonstrate reach of Gavi
support.
M. 6 Economic benefits
unlocked
Calculated as cost -of-illness
(COI) averted. COI includes
treatment and transport costs,
caretaker wages and
productivity loss due to
disability and premature death.
Demonstrate Gavi impact on
economic productivity.






1 Indicators for strategy goal 3 have yet to be defined. Measurement of SG3 pending Alliance
discussions on financing and Board decision on the updated eligibility, transition and co -financing policy. 2 Indicators underlined are included in the 2020 -2025 I nvestment Opportunity and will be used, in part,
to report on progress towards meeting commitments made in 2021 -2025 Investment opportunity.

6 July 2020

07 Review of the Gavi Gender Policy pdf

1



Board -2019 -Mtg -3-Doc 07


Section A: Executive Summary
Context
Gavi has had a Gender Policy to guide its programmatic work since 2008 . The original
policy was updated in 2013 to the current version . The current policy has been
revised by the Secretariat following a review process which included an independent
external evaluation , analysis, and extensive consultation s with country
re presentatives, partners, civil society organisations, gender and immunisation
experts and donors. In May 2020, the Programme and Policy Committee (PPC)
recommended that the Board approve the revised Gender Policy , congratulating the
Secretariat on the highly consultative and inclusive review process.
Questions this paper addresses
? How has the Gender Policy been revised as a result of the review?
? What is the relevance of this policy to the COVID -19 pandemic?
Conclusions
Gavi?s Gender Policy aims to support Gavi?s bold aspiration of ?Leaving no one
behind with immunisation? and to strengthen vaccine programmes and health
systems to increase equity in imm unisation. The revisions seek to better align the
policy with Gavi?s strategy for 2021 -2025 (Gavi 5.0) . With equity as the organising
principle, it focuses on ensuring zero -dose and underimmunised children,
individuals and communities are sustainably reach ed with routine immunisation
services. The revised policy is more ambitious and identifies areas for gender -
responsive and transformative interventions, underpinned by an updated theory of
change which places a new focus on understanding, learning and part nering as
approaches to achieve the policy goals. It uses inclusive, non -binary language and
considers how other socio -cultural factors can compound gender -related barriers.
In addition to caregivers, the policy focuses on two new groups: healt h workers an d
adolescents, both of wh om face specific gender -related barriers to providing or
accessing healthcare.
The Secretariat is working closely with partners to better understand the gendered
impacts of the COVID -19 pandemic and proactively suggesting potential
approaches to addressing these challenges.
The Secretariat is presenting a revised Gender Policy to the Board for approval (see
Annex B).
SUBJECT : REVIEW OF THE GAVI GENDER POLICY
Agenda item: 07
Category: For Decision
Report to the Board
24 -25 June 20 20

6 July 2020

07 Annex A Implications pdf

Report to the Board
Board -2020 -Mtg -3-Doc 07-Annex A
Annex A: Implications
? Risk implication and mitigation, including information on the risks of
inaction . Gender has been identified as an important determinant of health and
immunisation outcomes . Inaction would result in Gavi not being able to reach
as many zero -dose and underimmunised children . ?G ender -focus? has been
elevated to a principle in Gavi 5.0, key to achieving the vision , so this policy
update is necessary to ensure Gavi programming is fit for purpose.
? Impact on countries. Gavi -supported c ountries will require support to identify
and address gender -related barriers. The 5.0 vision and this policy raise the
priority level of gender within the context of equity and countries will be
encouraged to programme their health system strengthening funding to find and
reach zero -dose and underimmunised children, an important part of which is
addressing gender considerations.
? Impact on Alliance. As a cross -cutting policy, the success of implementation
will be driven in large part by Alliance partners who will play an integral role in
supporting achievement of the policy objectives. A deliverable of the policy is
to ?Partner? effectively , which includes mainstreaming gender throughout the
Alliance to ensure alignment on goals regarding gender. Implementation of
more gender -focused activities will be supported through Gavi?s different
funding channels and through its engagement with partners.
? Legal and governance implications. There are no legal implications with
respec t to the content of this report. The gender balance of governance
structures has been reviewed alongside the policy review and can be found in
Doc 01f .

6 July 2020

07 Annex B Revised Gender Policy pdf



Report to the Board

Board -2020 -Mtg -3-Doc 07-Annex B

Annex B: Revised Gender Policy






DOCUMENT ADMINISTRATION
VERSION
NUMBER APPROVAL PROCESS DATE
3.0 Reviewed by: Programme and Policy
Committee
2.0 ? 10 October 2013
3.0 ? 26 May 2020
Approved by: Gavi Alliance Board

1.0 ? 26 June 2008
Effective from 1 July 2008
2.0 ? 21 November 2013
Effective from 1 January 2014
3.0 ? 24 June 2020
Effective from: 1 July 2020
Next review: At the request of the Board
Gavi , the Vaccine Alliance
Gender Policy
Version 3.


Report to the Board
Board -2020 -Mtg -3-Doc 07-Annex B
2
Definitions
o Zero -dose children are those who have not receive d any routine vaccine. For
operational purposes, Gavi measures zero -dose children as those who have not
received their first dose of diphtheria -tetanus -pertussis containing vaccine (DTP1).
o Under immunised individuals include children, adolescents and adults that are
missing their full course of vaccination.
o Caregiver is a person who regularly or intermittently cares for an infant or child.
Examples include mothers, fathers, grandparents and siblings .
o Sex refers to the biological characteristics that define humans as female, male or
intersex and is typically assigned at birth.
o Gender is about the roles, norms and behaviours that society consider s appropriate
for women, men, girls, boys, and those with diverse gender identities , such as
transgender . These are socially constructed , fluid , and var y widely within and across
time, cultures, religions, class and ethnicity.
o Gender -related barrier s are related to deep rooted social and cultural norms about
the roles of women, men , and those with diverse gender identities , that create
obstacles to equitable access and use of health services . For example, when
caregivers, primarily women , have not completed secondary educat ion , lack decision -
making power, or are unable to move freely outside their homes, there is a greater
likelihood that they will not take their children to get vaccinated . In addition, lack of
male en gagement can contribute to poor child health outcomes .
o Intersectionali ty refers to the overlap between multiple forms of inequality or
discrimination which create obstacles for individuals, for example, access and use of
health services. Gender identity can intersect with additional factors, including but not
limited to age, geographical location, education, ethnicity, religion, class,
socioeconomic status, disability, migration/refugee status, sexual orientation.
o Gender equity is the process of being f air to women , men and those with diverse
gender identitie s. It recogniz es that individual s of different gender identities have
different needs, power and access to resources, which should be identified and
addressed to rectif y the imbalance . Addressing gender e quity leads to equality .
o Gender equality is the absence of discrimination based on a person?s sex or gender
identity . It means ensuring that the same opportunity is accessible to each person such
as access to and control of social, economic and political resources, including
protection under the law ( e.g. , health services, education and voting rights).
o Gender -responsive approaches adopt a gender lens to consider individual needs of
different gender identities without necessarily chang ing the larger contextual issues
that lie at the root of the gender inequities and inequalities . For example, employing
female health workers will facilitate enhance d immunisation service acceptance and
uptake, but would not address the underlying cultural barrier that prevents female
caregivers from seeking immunisation services from male health workers.
o Gender -transformative approaches are those that attempt to re -define and change
existing gender roles , norms, attitudes and practices. These interventions tackle the
root cause s of gender inequity and inequality and reshape unequal power relations.

6 July 2020

07 Annex C Gender Policy Monitoring Evaluation Framework pdf



Report to the Board
Board -2020 -Mtg -3-Doc 07-Annex C

Classified as Internal
Annex C: Gender Policy Monitoring and Evaluation Framework

Theory of Change

Report to the Board
2
Board -2020 -Mtg -3-Doc 07-Annex C
Classified as Internal
Monitoring Framework
The implementation and adherence to the Gender Policy will be monitored by the Gavi Secretariat
on an ongoing basis. This policy also points to the need for better data to be able to assess the
need for, and progress of, interventions to tackle gender -related barriers. The implementation of
the policy will be monitored at the strategic, process and country -levels. With the implementation
of Gavi?s new strategy beginning in 2021 these indicators and monitoring processes are subject
to ev olution and addition.
Strategy -level
Gavi?s strategy for 2021 -2025 (Gavi 5.0) includes a principle around ?gender -focus?. Monitoring of
gender -related performance will sit under Strategic Goal 2: Strengthen health systems to increase
equity in immunisatio n. The specifics will be detailed in strategic implementation monitoring
documents.
Process -level
Gavi?s progress in implementing the policy will be monitored through process -level indicators on
an annual basis, where possible. These process -level indicat ors map to the six deliverables
articulated in the Policy and theory of change and will be monitored at an aggregate level across
countries or Alliance partners, and not at individual country or partner level. As gender -related
barriers are highly context specific, outcomes will not be monitored at aggregate level but rather
country by country, as described in the following section. The process -level indicators will be
refined and finalised alongside the new strategy, and include, but not be limited to, tra cking the
following activities:
Understand
? Number of people trained in gender with Gavi funds (disaggregated by place of work:
Gavi Secretariat, Alliance partner, country EPI programme)
? % of teams mainstreaming gender into their processes and deliverables
Advocate
? Number of priority public policy outcomes for which Gavi has driven inclusion of gender
language and positioning (at global, regional and country levels)
? % of countries that include gender -related activities in their National Immunisa tion Strategies
Identify
? % of countries demonstrating that they have assessed gender -related barriers to
accessing immunisation services as part of their broader analysis of barriers to reaching
zero dose (using for example, equity assessment, gender situa tional reports)
Reach
? % of countries prioritising at least one intervention to tackle gender -related barriers
? % of countries budgeting for at least one intervention to tackle gender -related barriers
? % of countries tracking their progress in tackling gend er-related barriers with at least one
context -relevant indicator
? % of HPV support applications that plan for integrated services for adolescents

6 July 2020

08 Review of decisions No paper pdf

1



Board -2020 -Mtg -3-Doc 08
Report to the Board
24 -25 June 20 20

















SUBJECT: REVIEW OF DECISIONS
Agenda item: 08
No paper

6 July 2020

09 Closing remarks No paper pdf

1



Board -2020 -Mtg -3-Doc 09
Report to the Board
24 -25 June 20 20

















SUBJECT: CLOSING REMARKS
Agenda item: 09
No paper

Board presentations

3 July 2020

05b CEPI Briefing presentation pdf

COVAX Portfolio
Briefing to the Gavi Board
June 25, 2020
Richard Hatchett, MD
CEO, Coalition for Epidemic Preparedness Innovation
2
Our mission
CEPI accelerates
development of
vaccines against
emerging infectious
diseases and enables
equitable access to
these vaccines for
affected populations
during outbreaks
Last updated: 5 Aug 2020

Subscribe to our newsletter